
Pfizer’s Sasanlimab Combo Shows Significant Event-Free Survival Benefit in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Pfizer’s Sasanlimab Combination Significantly Extends Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer Patients Pfizer Inc. (NYSE: PFE) today announced encouraging results from the pivotal Phase 3 CREST trial, evaluating the efficacy and safety of sasanlimab, an investigational anti-PD-1…













